Breast neoplasm

This phase II trial tests whether a planned sequence of targeted therapies can eliminate HER2+ metastatic breast cancer and allow patients to stop treatment. The study enrolls people with stage IV HER2+ breast cancer at diagnosis. Participants receive a series of drug combination…

This study tests whether giving fluzoparib (a PARP inhibitor) together with camrelizumab (an immunotherapy) before surgery can make HER2-negative breast cancer disappear completely in people with an inherited BRCA mutation. The trial enrolls 64 patients with early or locally adva…

This study tests whether a blood test that looks for cancer DNA (ctDNA) can find breast cancer returning earlier than usual scans or exams. About 976 people with HR-positive/HER2-negative early breast cancer who had surgery will give blood samples over time. If the test shows sig…

This early-phase study tests a new drug called HLD-0117 in about 33 women with a type of advanced breast cancer (ER-positive) that has spread and stopped responding to standard therapies. The main goals are to check the drug's safety and find the right dose, while also seeing if …

This study tests whether adjusting cancer drug doses for people with the Duffy null blood trait can reduce treatment delays and dangerous fevers. About 90 participants with multiple myeloma or triple-negative breast cancer will receive standard chemotherapy with modified dosing g…

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: fir…

This study looks at women with breast cancer that has spread to lymph nodes under the arm, found before surgery. Normally, doctors remove many lymph nodes, which can cause arm swelling and pain. The trial tests if removing only the first few affected nodes is just as effective fo…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This study tests a new drug called elacestrant against standard hormone therapy in people with a certain type of early breast cancer (ER+/HER2-) that has spread to lymph nodes and has a high chance of returning. About 4,220 participants will be randomly assigned to receive either…

This phase III trial tests whether proton craniospinal irradiation (pCSI) can improve survival compared to standard involved-field radiation therapy (IFRT) for patients with breast or non-small cell lung cancer that has spread to the lining of the brain and spinal cord (leptomeni…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…

This phase 3 trial is testing a new drug called palazestrant (OP-1250) combined with ribociclib against the standard letrozole plus ribociclib for people with ER+, HER2- advanced breast cancer who haven't had prior treatment. About 1,000 participants will be randomly assigned to …

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This early-stage trial is testing an investigational drug called GIM-122 in adults with advanced solid tumors that have not responded to standard treatments, including PD-1/PD-L1 inhibitors. GIM-122 is a special antibody designed to fight cancer in two ways. The study aims to fin…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

This study follows 138 adults in Bulgaria and Slovenia with HER2-low advanced breast cancer who are taking trastuzumab deruxtecan (T-DXd), a targeted therapy. Researchers will track how long patients go before needing a different treatment or dying. The goal is to see how well T-…

This early-phase trial is testing a new drug called BL-M07D1 in people with advanced HER2-positive or low-expression breast cancer and other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then testing that…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This phase 3 trial is testing a daily pill called giredestrant in 300 people with ER+/HER2- early breast cancer who had to stop standard aromatase inhibitors due to side effects. The study will track how well patients stick with the treatment, their quality of life, and any side …

This phase 2 trial tests whether injecting the experimental drug INT230-6 directly into the tumor before standard chemotherapy and immunotherapy can improve outcomes for people with early triple-negative breast cancer (TNBC). About 61 participants will be randomly assigned to rec…

This study asks whether a dose-dense chemotherapy combination called CMF (cyclophosphamide, methotrexate, and fluorouracil) can be a practical alternative to the standard AC regimen (doxorubicin and cyclophosphamide) for people aged 70 and older with early-stage breast cancer. Th…

This study tests whether a new treatment called Bria-IMT, given with an immunotherapy drug, helps people with advanced metastatic breast cancer live longer compared to standard chemotherapy. About 404 adults whose cancer has not responded to other treatments will participate. The…

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This study tests a new drug called YH42946 in people with advanced solid tumors that have certain gene changes (HER2 or EGFR). The main goals are to check safety and see if the drug shrinks tumors. About 161 adults who have run out of standard options will take part.

This phase 2 trial is testing whether adding evorpacept to standard trastuzumab and chemotherapy can shrink tumors in people with metastatic HER2-positive breast cancer who have already tried the drug Enhertu. About 120 participants will receive the combination intravenously. The…

This phase 2 trial is testing a type of radiation called craniospinal irradiation that avoids the hippocampus, a brain area key for memory. It is for people with breast or lung cancer that has spread to the fluid and lining around the brain and spinal cord. The goal is to see if …

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), given alone or with pembrolizumab, helps people with advanced triple-negative breast cancer live longer or keep their cancer from growing. About 1,000 adults whose cancer has spread and who have not had prior…

This phase 2 study tests an investigational drug called telisotuzumab adizutecan in about 100 people aged 12 and older with advanced solid tumors that have a specific genetic change (MET amplification). The drug is given through an IV and aims to shrink tumors or stop them from g…

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This study tests a new drug, patritumab deruxtecan, against standard chemotherapy or another drug for people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if the new drug helps people live longer or keeps the cancer from growing. About 1000 particip…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This phase 3 trial tests whether a new drug (MK-2870), alone or with another drug (pembrolizumab), works better than standard treatments for people with a common type of advanced breast cancer (HR+/HER2-). About 1,200 participants whose cancer has worsened after hormone therapy w…

This study compares two treatments for people with high-stage, estrogen-positive, HER2-negative breast cancer that has a low genetic risk of returning. One group gets standard hormone therapy plus a targeted pill (ribociclib), while the other gets chemotherapy first, then the sam…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This study looks at whether women over 45 with a low-risk type of early breast cancer (DCIS) can avoid radiation after breast-conserving surgery. A genetic test helps identify those with a very low chance of the cancer coming back. The goal is to see if skipping radiation is safe…

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This trial is testing an oral drug called elacestrant in Japanese patients with a specific type of advanced breast cancer (ER+/HER2-) that has a mutation in the ESR1 gene and has progressed after prior endocrine therapy including a CDK4/6 inhibitor. The study aims to see if elace…

This phase 2 trial is testing whether giving a short course of targeted radiation (SBRT) followed by a reduced-dose chemotherapy (nab-paclitaxel) plus an immunotherapy drug (toripalimab) before surgery can improve outcomes for people with HR-positive, HER2-negative breast cancer.…

This trial tests whether a form of ionized gas, called non-thermal plasma, can be safely applied to the area where a breast tumor was removed during surgery. The goal is to find the highest safe dose and see how well patients tolerate it, while also checking cosmetic effects. Adu…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This phase 3 trial is testing whether adding a targeted therapy called Sacituzumab tirumotecan (Sac-TMT) to standard chemotherapy and immunotherapy (pembrolizumab) can better eliminate cancer before surgery in people with high-risk, early-stage triple-negative or hormone-receptor…

This early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This study is testing whether a simple blood test that looks for cancer DNA can help doctors decide when to start a targeted therapy (CDK4/6 inhibitor) in people with intermediate-risk HR+ HER2- breast cancer. About 725 participants will have their blood tested every 3 months for…

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This study is testing a program called WeCan-Rural for breast cancer survivors living in rural, underserved areas. The program includes 12 weekly video sessions to help manage symptoms like pain and fatigue, and build healthy habits around eating, exercise, and weight. The goal i…

This study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…

This trial is testing whether young women under 40 with a very early, low-risk form of breast cancer called ductal carcinoma in situ (DCIS) can safely avoid radiation therapy after having breast-conserving surgery. Instead of radiation, participants will be closely monitored, and…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This trial tests a combined imaging and treatment method called HMIgFUS for breast tumors. The approach uses focused ultrasound waves to heat and destroy tumor tissue, while a special imaging technique monitors the process in real time by measuring tissue stiffness. The study inc…

This study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…

This trial is asking whether women with a very early, non-invasive breast condition called ductal carcinoma in situ (DCIS) can safely skip radiation therapy after having breast-conserving surgery. The study focuses on women aged 40 and older with low- or intermediate-risk DCIS th…

This study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…

This trial tests an experimental oral drug called TT-702 in people with advanced solid tumors. The drug works by blocking a protein that tumors use to hide from the immune system. The study aims to find the safest dose of TT-702 when given alone and in combination with an immunot…

This Phase 2 trial is testing whether the drug sacituzumab govitecan (Trodelvy) can shrink tumors in people with a specific type of advanced breast cancer (HR+/HER2 low or ultra low) who have already received another targeted drug called T-DXd. The study will enroll 75 participan…

This early-phase study tests a combination of two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. The main goal is to find safe doses and understand side effects. About 36 people will take part, and the study is currently re…

This early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…

This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sar…

This phase 3 trial tests whether adjusting tamoxifen doses based on individual metabolism can reduce the number of breast cancer patients who stop treatment early due to side effects. About 1,100 premenopausal or perimenopausal women with hormone-sensitive breast cancer will rece…

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

This early-stage trial tests a new drug called COM503, alone or with another drug zimberelimab, in 200 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is a first-in-human study, so effe…

This early-stage trial tests a new oral drug called RGT-419B, given alone or with hormone therapy, in 64 adults with a specific type of advanced breast cancer (HR+/HER2-) that has worsened after prior treatment. The main goal is to check safety and find the right dose, while also…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This phase 2 trial tests whether giving the chemotherapy drug capecitabine in a flexible, response-based way (adaptive therapy) can better control metastatic ER-positive breast cancer. About 35 adults with advanced, hormone-resistant disease will receive doses that are adjusted b…

This early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.

This early-phase trial tests a new drug called ZEN003694 combined with immunotherapy (pembrolizumab) and chemotherapy (nab-paclitaxel) in 57 people with advanced triple-negative breast cancer. The goal is to find a safe dose and see if the combo can shrink tumors or slow the canc…

This trial tests whether time-restricted eating (TRE) — a 16:8 fasting schedule — is feasible for patients with HER2-negative breast cancer undergoing neoadjuvant chemotherapy. Participants will follow TRE for 16 weeks while receiving chemo, and researchers will measure how many …

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This early-stage trial tests a new drug called HRS-6209 combined with standard hormone therapies (fulvestrant or letrozole) in people with a certain type of advanced breast cancer (HR-positive/HER2-negative). The main goal is to check safety and find the right dose. About 15 part…

This trial is testing whether a genomic test can identify early-stage breast cancer patients who might safely skip radiation to the internal mammary lymph nodes. Participants have 1-3 positive lymph nodes and are considered at intermediate risk. Half will receive standard radiati…

This Phase 2 trial tests an oral form of the chemotherapy drug paclitaxel, taken daily or three times a week, for people with advanced HER2-negative breast cancer. The study first finds the best dose of the oral pill alone, then combines it with the immunotherapy toripalimab to s…

This study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has a PIK3CA gene change and has stopped responding to hormone therapy. About 500 participants in China will receive inavolisib as part of their regular care. Rese…

This phase 2 trial is testing whether adding a drug called inavolisib to two standard treatments (ribociclib and fulvestrant) can shrink tumors or slow cancer growth in people with advanced hormone-receptor-positive, HER2-negative breast cancer that has a specific genetic change …

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …

This early-phase trial is testing a new drug called BMS-986517 in about 315 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug …

This phase III trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can prevent breast cancer from returning in people with a specific high-risk type of hormone receptor-positive, HER2-negative breast cancer. About 3,680 participants with sta…

This phase 3 trial is testing two oral drugs, camizestrant and ribociclib, as a first treatment for people with ER-positive, HER2-negative advanced breast cancer. The goal is to see if the combination can delay the need for next cancer therapy. About 150 participants will take th…

This phase II trial is testing whether an anti-viral drug called valganciclovir (Valcyte) can help treat breast cancer that has spread to the brain. The study includes 28 adults with progressive brain metastases who also have evidence of a common virus called CMV. Participants ta…

This study looks at whether adding a tumor bed boost to standard whole breast radiation after breast-conserving surgery helps women with HER2-positive breast cancer. It will track recurrence, survival, and side effects over seven years. The goal is to see if the extra radiation d…

This phase 2 trial tests whether a probiotic blend called WBF-038 can prevent bone loss in women with early-stage hormone receptor-positive breast cancer who are about to start aromatase inhibitor therapy. Aromatase inhibitors lower estrogen, which can weaken bones. The study wil…

This early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…

This study tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy in about 500 people with advanced triple-negative or ER-low breast cancer who cannot receive immunotherapy. The drug is designed to target and kill cancer cells while sparing hea…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This study tests a new drug called GDC-4198, alone or combined with another drug (giredestrant), against a standard treatment (abemaciclib plus giredestrant) in people with advanced ER+/HER2- breast cancer that has worsened after prior CDK4/6 inhibitor therapy. The trial has two …

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This study tests a new oral drug called AVZO-023, which blocks a protein (CDK4) that helps cancer cells grow. It is being tested alone or with other drugs in 380 adults with advanced solid tumors, especially a type of breast cancer called HR+/HER2-. The goal is to find a safe dos…

This phase 2 trial is testing whether a less extensive lymph node surgery, called targeted axillary dissection (TAD), can safely control cancer in women aged 45 and older with early-stage ER+ breast cancer that has spread to lymph nodes detected by ultrasound. Participants will h…

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This early-stage trial tests the safety and best dose of two oral drugs, ZEN003694 and binimetinib, taken together. It is for people with advanced solid tumors that have RAS pathway changes or triple-negative breast cancer that has spread or cannot be removed. The goal is to find…

This study tests whether adding a personalized vaccine (made from unique tumor proteins) to a combination of chemotherapy and two immunotherapy drugs can better control metastatic triple-negative breast cancer. About 70 participants will be randomly assigned to receive the vaccin…

This study looks at how well ribociclib, a targeted cancer drug, works when added to hormone therapy for people with HR+ HER2- stage II or III breast cancer. It will follow about 2,766 patients in Russia, comparing those who get ribociclib plus hormone therapy to those who got ho…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This Phase 3 trial tests whether elacestrant, a new hormone therapy, can prevent distant metastasis better than standard hormone therapies in 220 patients with ER+/HER2- breast cancer whose blood tests show signs of cancer DNA (ctDNA) but no visible spread. Participants are rando…

This early-stage trial tests a new drug called MEN2312, alone or with another drug (elacestrant), in 240 adults with advanced breast cancer that has specific genetic changes. The main goals are to find a safe dose and check for side effects. It is the first time MEN2312 is being …

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This study tests whether using inhaled budesonide (a steroid commonly used for asthma) for one year can stop lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently had lung inflammat…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This Phase 3 trial tests whether the drug elacestrant can help prevent breast cancer from coming back in people with high-risk HR+/HER2- early breast cancer. About 1,520 participants will receive either elacestrant or standard hormone therapy for up to 7.5 years. The study compar…

This trial tests several cancer drugs in children and young adults with solid tumors. It uses a master protocol to test different drug combinations more efficiently. About 105 participants will receive one of eight drugs, including ramucirumab, cyclophosphamide, and others. The g…

This study tests two experimental drugs, camizestrant and atirmociclib, in 24 people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has worsened after prior treatment. The main goal is to check safety and how the body processes the drugs, with ea…

This study tests whether adding a fasting-mimicking diet and exercise to standard chemotherapy and immunotherapy can improve treatment results for people with early-stage triple negative breast cancer. About 356 participants will be randomly assigned to receive either the lifesty…

This trial tests whether a personalized exercise program can safely help cancer survivors improve their physical fitness and quality of life. Participants who have finished curative treatment at least two months ago will receive a tailored plan based on heart, lung, and muscle as…

This phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (MK-2870) to the immunotherapy pembrolizumab can better prevent breast cancer from coming back in people with triple-negative breast cancer who still had tumor after initial treatment. About 1,5…

This phase 3 trial tests an immunotherapy called GLSI-100 in 750 people with HER2-positive breast cancer who are at high risk of their cancer returning after standard treatment. Participants receive a series of injections over a year to help their immune system target and destroy…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This study tests a new oral drug called imlunestrant in premenopausal women with estrogen receptor-positive, HER2-negative breast cancer. Some participants will also receive a drug to suppress ovarian function. The effects on tumor cells and ovaries will be compared with those of…

This study tests two different doses of inavolisib combined with fulvestrant in people with a specific type of advanced breast cancer (PIK3CA-mutated, HR-positive, HER2-negative). About 80 participants whose cancer worsened after prior treatment will receive the drug combo. The g…

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and CDK4/6 inhibitors can better control advanced HR+ HER2- breast cancer with a PIK3CA mutation. About 920 adults who have not had prior treatment for advanced disease will participate. The goal i…

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This study is for women whose breast cancer has come back after initial breast-conserving surgery and whole breast radiation. The standard treatment after repeat surgery is radiation twice a day for 30 sessions. This trial tests whether giving radiation once a day for 15 sessions…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study tests a combination of two drugs, elacestrant and abemaciclib, in people with a specific type of breast cancer (ER-positive, HER2-negative) that has spread to the brain. The goal is to see if the combination can shrink or control brain tumors. The trial involves about …

This study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This phase 2 trial is testing whether the investigational drug datopotamab deruxtecan (Dato-DXd) can safely and effectively treat HER2-negative breast cancer that has spread to the brain. The study enrolls adults with metastatic breast cancer who have brain metastases that are ei…

This study tests a new drug called BGB-43395 combined with letrozole against standard CDK4/6 inhibitor drugs (abemaciclib, palbociclib, or ribociclib) plus letrozole for people with advanced or metastatic HR+/HER2- breast cancer who have not had prior treatment for advanced disea…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This early-phase trial is testing a new drug called AZD8421, alone or with other cancer drugs, in people with advanced ER+ breast cancer or high-grade ovarian cancer. The study aims to find safe doses and see if the drug can shrink tumors. About 564 women aged 18 and older will t…

This early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This phase 3 study tests whether adding capivasertib to standard hormone therapy helps people with HR+/HER2- advanced breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib plu…

This study tests whether adding the drug inavolisib to standard hormone therapy and a CDK4/6 inhibitor can help people with a specific type of advanced breast cancer (PIK3CA-mutated, HR+, HER2-). About 450 adults whose cancer has not been treated yet in the advanced setting will …

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…

This trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…

This early-stage trial tests a new drug, GDC-0587, alone or with another drug (giredestrant), in people with advanced ER-positive, HER2-negative breast cancer whose cancer worsened after prior CDK4/6 inhibitor therapy. The study aims to find safe doses and check for side effects.…

This phase 2 trial tests whether adding the experimental drug evexomostat (SDX-7320) to standard chemotherapy (eribulin) works better than chemotherapy alone for people with metastatic triple-negative breast cancer who also have metabolic dysfunction (like insulin resistance). Th…

This Phase 3 study compares a new daily pill, giredestrant, against the standard shot fulvestrant, both given alongside a CDK4/6 inhibitor, in about 1,050 people with ER+/HER2- advanced breast cancer that has become resistant to prior hormone therapy. The goal is to see if girede…

This study is testing several different drug combinations in people with advanced ER-positive breast cancer that has stopped responding to prior treatments. The trial is designed like an 'umbrella,' allowing new drug combos to be added as they become available. About 316 particip…

This phase 3 trial is testing whether 6 months of HER2-targeted therapy (trastuzumab and pertuzumab) works as well as the standard 12 months for people with early-stage HER2+ breast cancer who had a complete response to initial chemotherapy. About 1,500 participants will be rando…

This study tests whether adding ivermectin (a drug used for parasitic infections) to standard immunotherapy drugs (balstilimab or pembrolizumab) can shrink tumors in people with metastatic triple-negative breast cancer. The trial has two phases: first, finding the safest dose of …

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…

This study compares two drug combinations for people with a type of advanced breast cancer (HR+/HER2-) that has a specific genetic change (PIK3CA mutation) and has worsened after prior treatment. About 540 adults will receive either the experimental drug RLY-2608 plus fulvestrant…

This trial investigates whether tumor-infiltrating lymphocytes (TILs) — immune cells taken from a patient's own tumor — can be expanded in the lab and infused back to attack cancer. It enrolls adults aged 18 to 75 with advanced solid tumors who have failed standard treatments. Th…

This study tests a new drug, RO7771950, designed to reach the brain, for people with HER2-positive breast cancer that has spread to the brain or other organs. About 650 participants will receive either the new drug or an existing drug (tucatinib), both combined with standard ther…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This phase 3 trial is for people with early-stage triple-negative breast cancer who had a complete response to chemotherapy plus the immunotherapy drug pembrolizumab before surgery. It compares continuing pembrolizumab for 27 weeks after surgery versus simply watching and waiting…

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This study tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with early-stage triple-negative breast cancer. About 34 participants will receive the combination every three weeks for six cycles, then undergo surgery. …

This study tests a vaccine called STEMVAC, given with chemotherapy, for people with a type of advanced breast cancer (triple-negative) that has spread. The vaccine is designed to teach the body's immune system to find and destroy cancer stem cells. About 20 adults with PD-L1 nega…

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

This trial is testing an oral version of the chemotherapy drug paclitaxel, given after standard intravenous chemo, for people with triple-negative breast cancer. The study aims to find the safest and most effective dose of the oral paclitaxel. Participants will receive four cycle…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This study looks at whether adding chemotherapy to standard hormone therapy (which suppresses ovarian function) can better prevent breast cancer from coming back in premenopausal women with early-stage, hormone-sensitive breast cancer. About 3,960 participants will be randomly as…

This study is for people with a common type of early breast cancer (HR-positive, HER2-negative) that is likely to respond to hormone therapy. Researchers want to see if taking hormone pills for 8 months works just as well as chemotherapy, but with fewer side effects. Participants…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…

This Phase 1 trial is testing ZOLADEX (goserelin), a hormone-blocking implant, in 88 premenopausal women with HR+/HER2- advanced breast cancer. The goal is to see if it can temporarily shut down ovarian function, which may help control the cancer. Participants receive two injecti…

This trial is testing an oral form of the chemotherapy drug paclitaxel, given alongside standard anti-HER2 therapies (trastuzumab and pertuzumab), for people with HER2-positive breast cancer. The goal is to find the safest and most effective dose of the oral paclitaxel when used …

This trial is testing a new way to deliver radiation therapy for early-stage breast cancer. Instead of the usual weeks of daily radiation after surgery, this approach gives a shorter, more intense course of radiation before the tumor is removed. The study aims to find the safest …

This phase 3 trial tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with advanced triple-negative breast cancer (TNBC) live longer without their cancer growing. Participants have TNBC that cannot be treated with current PD(L)1 immunotherapie…

This phase 3 trial is testing whether a targeted drug called sacituzumab govitecan (Trodelvy), alone or combined with the immunotherapy pembrolizumab (Keytruda), can effectively treat low-risk triple-negative breast cancer before surgery. The study aims to see if these drugs can …

This trial tests whether starting upper limb rehabilitation exercises one day before breast cancer surgery can reduce the risk and severity of arm lymphedema (swelling) after surgery. Half of the participants will receive individualized exercise instruction, while the other half …

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…

This early-stage trial tests an investigational cancer vaccine called ITI-5000 in 60 people with stage II-III triple-negative breast cancer who have finished standard treatment. The vaccine uses self-amplifying RNA to teach the immune system to attack cancer cells. The study firs…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…

This study tests a device called SAVI Scout MD, which uses tiny radar reflectors placed in the breast before surgery to help surgeons locate and remove tumors more precisely. The goal is to see if this method leads to complete tumor removal with clear margins, potentially reducin…

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

This phase II trial is testing whether adding a new oral drug called culmerciclib to standard anti-HER2 therapy and hormone therapy can help maintain control of advanced breast cancer that is both hormone receptor-positive and HER2-positive. The study enrolls women with metastati…

This early-phase trial is testing an experimental drug called ROSE12, alone or combined with other anti-tumor agents, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to evaluate safety, determine the best dose, and look…

This early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…

This trial tests a multicomponent adherence intervention designed to help patients with metastatic breast cancer and cardiovascular disease take their endocrine therapy, CDK4/6 inhibitors, and heart medications as prescribed. The study enrolls 35 adults who have reported some non…

This Phase 2 trial is testing two experimental drugs (SSGJ-705 and SSGJ-612) with or without chemotherapy in 150 adults with advanced HER2-positive solid tumors, including colorectal, bladder, breast, bile duct, and stomach cancers. The goal is to see if the combination can shrin…

This phase 3 trial is testing an experimental drug called VC004 in people aged 12 and older with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see whether VC004 capsules can shrink tumors and control the disease. All participants receive th…

This trial tests whether using only hormone-blocking drugs can control breast cancer in women aged 70 and older who have a low-risk, hormone-sensitive tumor. Participants receive standard endocrine therapy instead of surgery or radiation. The goal is to see if this gentler approa…

This trial tests whether a silicone film called Mepitel Film can prevent radiation dermatitis — painful skin irritation — in breast cancer patients undergoing radiation therapy in Singapore's hot and humid weather. About 60 adults who have had breast cancer surgery and are schedu…

This large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…

This trial is testing whether a new antibody-drug conjugate called GQ1001, when combined with the oral drug pyrotinib, can safely shrink tumors in people with HER2-positive metastatic breast cancer that has stopped responding to earlier anti-HER2 treatments. The study enrolls abo…

This early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body proces…

This early-phase trial is testing an experimental drug called M3T01, a monoclonal antibody that targets a protein called FasL, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to see if M3T01 is safe and tolerable when given al…

This phase 3 trial is testing whether patients with early-stage triple-negative breast cancer who have a complete response to standard chemotherapy plus the immunotherapy drug pembrolizumab can safely stop pembrolizumab early instead of continuing it for an additional six months.…

This pilot study is testing whether partial breast irradiation alone — without first removing or sampling lymph nodes from the armpit — is safe for women age 40 and older with early-stage invasive breast cancer. All participants have had a lumpectomy but no sentinel node biopsy o…

This trial is testing whether combining an antibody called naxitamab, the chemotherapy drug gemcitabine, and specially engineered natural killer (NK) cells from a healthy donor can safely shrink tumors in people with advanced HER2-negative breast cancer that has spread. The cance…

This trial is testing an experimental drug called AT-1965 in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and then seeing whether the drug can shrink tumors. About 100 participants will…

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This phase 3 trial compares an experimental drug called BL-B01D1 to standard chemotherapy in people with a common type of breast cancer (HR+/HER2-) that has stopped responding to hormone therapy and cannot be removed by surgery. The study aims to see if BL-B01D1 can delay cancer …

This phase II trial is testing whether combining BL-B01D1, a targeted drug, with a PD-1 monoclonal antibody can shrink tumors in people with advanced triple-negative breast cancer that cannot be surgically removed or has spread. The study enrolls about 52 adults aged 18 to 75 who…

This study investigates whether patients with HER2-positive metastatic breast cancer who have had their disease controlled for at least two years on anti-HER2 therapy can safely stop that treatment. Participants must also have no detectable cancer DNA in their blood (ctDNA-negati…

This study tracks 108 patients with HR-positive, HER2-negative advanced breast cancer who are receiving abemaciclib combined with hormone therapy. Researchers are collecting real-world data on how long patients live without their cancer worsening, overall survival, and side effec…

This early-stage trial tests an experimental oral drug called APG-2449, alone or combined with another cancer drug, in people with platinum-resistant recurrent ovarian cancer or other advanced solid tumors. The study aims to find safe doses and understand how the drug works in th…

This study tests whether postmenopausal women with a very low-risk type of breast cancer (HR+ HER2-) can safely take hormone therapy for only 2-3 years instead of the standard 5 years. The goal is to maintain protection against cancer spread while reducing side effects and improv…

This study tests whether a behavioral program — time-restricted eating, nutrition education, and reducing sedentary time — can prevent the unhealthy fat buildup that often occurs during chemotherapy for breast cancer. Researchers will measure changes in visceral and muscle fat us…

This trial investigates whether adding simvastatin, a widely used cholesterol medication, to the standard hormone therapy letrozole can better slow the growth of hormone receptor-positive, HER2-negative breast cancer before surgery. About 40 adults with stage I-III breast cancer …

This trial tests whether a custom-made breast holder called VENUS SHELL™ can improve positioning and comfort during radiotherapy for early-stage breast cancer. Participants lie on their stomach while the device holds the breast in place, aiming to deliver precise radiation in sho…

This phase 2 trial tests an experimental drug called YL202 in people with advanced or metastatic breast cancer that has not responded to other treatments. The study includes patients with triple-negative breast cancer (TNBC) or hormone receptor-positive, HER2-zero or HER2-low tum…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This trial investigates whether women aged 60 and older with a very small, low-risk type of breast cancer can safely avoid hormone therapy after surgery. Participants will not receive standard drugs like tamoxifen or letrozole, and researchers will track cancer recurrence for up …

This trial tests SPEDOX-6, a version of the chemotherapy drug doxorubicin wrapped in a protein shell, in people with advanced solid tumors such as soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, and certain pancreat…

This clinical trial is testing a combination of three drugs—entinostat, pyrotinib, and endocrine therapy—in people with advanced triple-positive breast cancer (cancer that is both hormone receptor-positive and HER2-positive) whose disease has worsened after prior treatment with t…

This study tests whether personalized coaching based on patient typology helps women with HR+/HER2- early breast cancer stick with their ribociclib treatment longer. About 548 participants will either receive standard education or tailored coaching using a validated tool. The goa…

This study tests an experimental drug called HRS-6209 in combination with several other breast cancer treatments (fulvestrant, letrozole, HRS-8080, or HRS-1358) for people with advanced breast cancer that cannot be surgically removed or has spread. The trial includes two stages: …

This trial investigates whether a single, high dose of MRI-guided radiation given before surgery can completely eliminate low-risk breast cancer. Women aged 50 and older with small, early-stage tumors receive one radiation dose, then wait 6 to 12 months before surgery to see if t…

This study tests whether a bilingual smartphone app, combined with patient navigation, can help Latina breast cancer patients take their hormone therapy as prescribed. Many patients struggle with barriers like cost, insurance, or language that make it hard to stay on treatment. T…

This phase 1 trial tests an experimental drug called ACM-CpG, given as a shot into the muscle, in people with advanced solid tumors that have not responded to standard immunotherapy. The drug is designed to activate the immune system to attack tumors. The study aims to find the s…

This phase II trial tests whether combining three experimental antibody-drug conjugates (SHR-A1811, SHR-A1921, and SHR-A2102) with the immunotherapy drug adebrelimab can shrink tumors in people with HER2-negative advanced breast cancer. Participants must have already tried at lea…

This phase 1 trial tests an experimental drug called PA5 in adults with advanced solid tumors that have not responded to standard treatments. PA5 is designed to break down arginine, an amino acid some cancers need to grow. The study aims to find the safest dose and check for side…

This trial investigates whether combining high-intensity focused ultrasound (HIFU) with the immunotherapy drug toripalimab and standard chemotherapy can improve outcomes for people with ER+/HER2- breast cancer before they undergo surgery. The study enrolls women aged 18-75 with i…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…

This study tests a device called Addinex that stores opioid pills and releases them only with a unique passcode. Adults having cancer-related surgery who expect to need opioids for pain will use the device instead of a standard pill bottle. Researchers will measure how many unuse…

This study tests whether adding the drug olaparib to standard trastuzumab and pertuzumab before surgery can improve outcomes for women aged 60 and older with HER2-positive breast cancer. Participants receive the combination for up to six cycles before surgery, and doctors check h…

This study tests a dendritic cell vaccine given directly into the spinal fluid for people with breast cancer that has spread to the lining of the brain and spinal cord (leptomeningeal disease). The vaccine is combined with either trastuzumab (for HER2-positive cancer) or nivoluma…

This phase 3 trial is testing whether premenopausal women with a common type of breast cancer (HR+/HER2-) can safely skip chemotherapy if their tumor responds well to hormone therapy before surgery. About 950 women will be randomly assigned to either standard surgery first or hor…

This study tests a program where clinical pharmacists provide personalized counseling to cancer patients taking oral anticancer drugs. The goal is to see if this support helps patients take their medication more consistently. Researchers will compare two groups of 80 patients eac…

This study tests whether adding a precise local treatment—like focused radiation or ablation—can help people whose cancer has a few new or growing spots while on standard therapy. Participants continue their usual medication while the resistant tumors are treated directly. The go…

This study follows 650 women aged 18 to 65 who receive Eurosilicone LunaXT silicone breast implants for cosmetic augmentation or reconstruction after mastectomy. Researchers track how often the implants rupture or cause severe capsular contracture (hardening of scar tissue) over …

This study tests a new drug, CAN016, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, and second, seeing if the drug shrinks tumors. About 90 participants will receive CAN016 every three wee…

This study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…

This trial investigates whether sulforaphane, a nutrient found in broccoli, can reduce heart damage caused by the chemotherapy drug doxorubicin in breast cancer patients. About 70 participants will receive either sulforaphane or a placebo alongside their chemotherapy. The study m…

This phase 3 trial tests whether a new drug called GQ1005 works better than the current standard treatment T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. Participants have already been treated with trastuzumab and a taxane. The …

This study is testing whether giving radiation therapy before surgery can shrink advanced breast tumors that didn't respond well to chemotherapy, making them operable. Researchers are also testing if a dietary supplement called beta-alanine and a special type of radiation (lattic…

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This phase 2 trial tests whether a new drug called culmerciclib, combined with fulvestrant, works better than standard CDK4/6 inhibitors plus fulvestrant for people with HR-positive, HER2-negative breast cancer that has worsened after first-line hormone therapy. About 98 women ag…

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This study tests a new treatment using specially engineered immune cells (4SCAR-T cells) that target three different markers on breast cancer cells: GD2, Her2, and CD44v6. The goal is to see if this approach is safe and can shrink tumors in people with advanced or relapsed breast…

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This phase 2 trial is testing whether a simple blood test that looks for tumor DNA (ctDNA) can help doctors decide when to switch treatments in people with metastatic triple-negative breast cancer. The study compares standard care with a strategy where ctDNA results guide an earl…

This phase 3 trial tests whether a shorter, higher-dose radiation schedule (3 weeks) is as safe and effective as the standard 5-week schedule for women with high-risk breast cancer who have had a mastectomy and immediate implant reconstruction. The study will enroll 506 women and…

This early-phase trial tests two radioactive drugs, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced solid tumors that have a protein called GRPR on their surface. These cancers include certain breast, prostate, and colorectal cancers that have stopped responding …

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This study tracks the safety and effectiveness of Piqray (Alpelisib) in people with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation). It includes postmenopausal women and men whose cancer worsened after hormone therapy. Researchers observe patients i…

This trial tests a new approach to breast reconstruction after cancer surgery. Doctors take a patient's own fat and mix it with a substance made from their blood (platelet-rich fibrin) to create a 'lipobolus' that fills the gap left by tumor removal. The goal is to see how much o…

This phase II trial is recruiting 120 women with advanced HER2-negative breast cancer to find out whether it is better to receive antibody drug conjugates (ADCs) before chemotherapy or after. Participants will be randomly assigned to one of two sequences, and researchers will com…

This early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …

This phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …

This study tests whether adding two immunotherapy drugs (CDX-1140 and CDX-301) to standard chemotherapy (PLD) is safe and helps control metastatic HER2-negative breast cancer. About 30 people with advanced cancer that has not responded to other treatments will take part. The goal…

This study is testing two different radiation schedules for women with early breast cancer who have had a lumpectomy. One group gets radiation over one week, the other over two weeks with an extra boost to the tumor site. Researchers will compare side effects, breast appearance, …

This phase 2 trial tests whether adding a PD-L1 antibody (adebrelimab) to a three-drug chemotherapy regimen (vinorelbine, cyclophosphamide, capecitabine) and either early or delayed radiotherapy can help control brain tumors in people with advanced HER2-negative breast cancer. Ab…

This study tests a new radiation approach for early breast cancer that uses real-time MRI guidance to deliver just three high-dose sessions over one week, instead of the usual several weeks. The goal is to see if this shorter treatment is safe, preserves the breast's appearance, …

This phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This study enrolls 400 women at high risk for breast cancer to see if a shorter, abbreviated MRI scan works as well as a full-length MRI for early detection. Participants will get MRI scans every 6 months. The goal is to develop faster, personalized screening that could make regu…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This trial tests whether a simplified heart ultrasound is as good as the standard comprehensive exam for detecting heart problems caused by breast cancer treatment. About 250 breast cancer patients will be randomly assigned to one of the two monitoring approaches. The study also …

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

This study looks at medical records from 925 women with newly diagnosed breast cancer to see if routine information—like blood tests and basic health data—can predict whether the cancer has already spread to distant organs. The goal is to build a prediction model that helps docto…

This study is testing a new type of PET scan that uses a radioactive tracer to detect a protein called TROP2 on breast cancer cells. The goal is to see if this scan can predict how well a targeted drug (ADC therapy) will work for each patient. About 60 adults with breast cancer w…

This trial is testing whether a new PET imaging agent can safely and effectively detect a protein called MMP14 on solid tumors. The study will involve about 30 adults with various solid tumors, such as melanoma, lung, or breast cancer. Each participant will receive the experiment…

This study is testing a new blood test called TuFEst that uses DNA fragments and deep learning to stage breast cancer and check if it has spread to lymph nodes. Researchers will enroll 269 breast cancer patients, including those having surgery and those receiving chemotherapy bef…

This early-phase study is testing whether a special PET scan tracer, originally used for prostate cancer, can detect metastatic triple negative breast cancer. Thirty women with advanced disease will receive both standard FDG PET and the new PSMA PET scan. The goal is to see if PS…

This study tests whether a new software tool, Kenko Breast AI+, can help doctors read breast MRI scans more accurately to diagnose breast cancer. About 200 adult women who may have breast cancer or are being monitored for it will take part. Researchers will compare MRI readings d…

This trial explores whether it is practical to offer routine brain MRI scans to people with HER2-positive metastatic breast cancer. Participants receive a baseline scan and are then randomly assigned to either two more scans over a year or no further scans. The goal is to see if …

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …

This trial is testing a new imaging system that combines two types of light-based technology to help surgeons see if any cancer cells remain at the edges of removed breast tissue during surgery. The goal is to reduce the need for repeat operations. About 120 people undergoing bre…

This phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain pr…

This study tests a new radioactive tracer called 68Ga-DOTA-BPP, which targets a protein (ACE) found on some cancer cells. Researchers want to see if it can improve PET/CT imaging for people with triple-negative breast cancer, a type that can be harder to detect. The trial involve…

This phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …

This study tests whether an artificial intelligence model can predict which patients with HR+/HER2- breast cancer will benefit most from chemotherapy given before surgery. Researchers will use pre-treatment MRI scans to classify patients into high- or low-benefit groups and compa…

This phase 2 trial tests a new radioactive tracer called 4FMFES for PET scans in people with advanced estrogen receptor positive (ER+) breast cancer. The tracer binds to estrogen receptors, allowing doctors to see where the cancer has spread anywhere in the body. The study aims t…

This study tests a new imaging agent called F18 FBPA, which is designed to light up cancer cells during a PET/CT scan. The agent targets a protein often found on solid tumors, potentially making tumors easier to see. Researchers want to find the best dose and timing for the scan,…

This study explores whether tiny particles called extracellular vesicles (EVs) in the blood can serve as a diagnostic and prognostic tool for breast cancer patients undergoing chemotherapy. Researchers will measure EV levels using a highly sensitive technology (SiMoA) in 35 women…

This study compares magnetic resonance imaging (MRI) with standard diagnostic techniques like mammography to see which method best finds and defines breast cancer. Researchers will enroll about 500 women with suspicious breast lesions to evaluate accuracy. The goal is to improve …

This study tests whether a genetic and epigenetic panel can predict heart damage caused by chemotherapy or immunotherapy in breast cancer patients. Researchers will analyze blood samples from 1,000 participants before and during treatment to see if certain genetic markers signal …

This study tests whether mobile health (m-Health) patient navigation—using phone apps for education, reminders, and motivation—can help more women in Kenyan primary care clinics get screened for breast cancer. The trial involves 800 women and aims to improve access to mammography…

This study tests a low-risk surgical procedure called LYMPHA, done at the same time as breast cancer lymph node removal, to prevent lymphedema—a chronic, painful arm swelling. About 80 women undergoing breast cancer surgery will be randomly assigned to receive LYMPHA or standard …

This study tests whether adding high-dose omega-3 fatty acids to low-dose tamoxifen can lower breast cancer risk more than tamoxifen alone. It includes 66 overweight or obese postmenopausal women at increased risk for breast cancer. The goal is to see if the combination improves …

This study tests whether adding a polygenic risk score (PRS) — a measure based on 313 genetic markers — to the standard CanRisk model can improve breast cancer risk prediction and prevention. About 100 women at increased risk will receive genetic counseling, a blood draw, and the…

This phase II trial tests whether a natural supplement called fisetin, found in strawberries, combined with exercise can prevent frailty in postmenopausal women who have had early-stage breast cancer. Fisetin may help clear aging cells that cause inflammation and damage healthy t…

This trial tests whether two physical therapies—Kinesio Taping and compression therapy—can relieve breast lymphedema, a common side effect of breast-conserving surgery and radiation that causes swelling, pain, and heaviness. About 99 women who have completed radiation and have ul…

This study tests whether two different exercise programs—one combining resistance training with cardio, the other with conditioning—have similar effects on muscle mass, fat mass, and blood pressure in women who have completed breast cancer treatment. Participants will exercise th…

This study tests whether custom 3D-printed external breast prostheses improve comfort, fit, and emotional well-being for women who have had a mastectomy without reconstruction. Fifty participants will receive a personalized prosthesis made from 3D scans of their chest. The goal i…

This study explores whether a brief behavioral program can help cancer patients and their sleep partners get better rest. The program teaches techniques like limiting time in bed and going to bed only when sleepy, aiming to improve sleep efficiency. Participants, who are couples …

This pilot trial tests whether a supervised exercise program is safe, helpful, and practical for adults who have had breast or gynecologic cancer. Participants will take part in a 12-week program combining strength and aerobic training under trained guidance. The study focuses on…

This trial tests whether a patient navigation program can help breast cancer survivors schedule and attend appointments for supportive services like counseling, exercise, and nutrition advice. Many survivors have unmet needs for such care, but participation is low, especially amo…

This study tests whether megestrol acetate, a drug often used for appetite loss, can prevent or reduce severe tiredness in 132 women with advanced breast cancer who are starting a treatment called trastuzumab deruxtecan (T-DXd). Participants will receive either megestrol acetate …

This pilot trial tests whether a 12-week virtual tai chi program can reduce joint pain in postmenopausal women with hormone receptor-positive breast cancer who are taking aromatase inhibitors. Participants are randomly assigned to tai chi classes or health education sessions. The…

This study tests two supportive care programs—meditation and discussion sessions—for people with advanced (stage IV) cancer and their family caregivers. Researchers want to see if these programs can reduce depressive symptoms and improve quality of life. About 400 patient-caregiv…

This pilot trial tests an adaptive stepped-care digital intervention to improve sleep in Chinese cancer survivors with mild-to-moderate insomnia. Participants first receive a self-guided web-based CBT-I program or a simple exercise program; those who don't improve may be stepped …

This study looks at whether a simple, non-needle ear acupressure technique can lower anxiety and pain in women having breast surgery after a first breast cancer diagnosis. About 66 women will either get standard care or standard care plus ear acupressure. The goal is to see if th…

This large phase 3 trial is testing whether giving lidocaine (a numbing medicine) during and after breast cancer surgery can reduce the chance of long-term pain. About 4,300 women having mastectomy or breast-conserving surgery will receive either lidocaine or a placebo. The main …

This study tests a one-session telehealth program that teaches pain coping skills to older women (55+) with breast cancer who have ongoing pain. Participants also receive five short follow-up calls. The goal is to see if this brief training can reduce pain severity and interferen…

This study tests a community-based course called BBCSI, led by trained peers, to see if it helps Black breast cancer survivors feel better day-to-day. About 46 women with early-stage breast cancer will take part. The goal is to improve quality of life, not to treat the cancer its…

This trial tests whether a 12-week slow jogging program can help breast cancer survivors sleep better, feel less tired, and enjoy a better quality of life. Women who have finished primary treatment for hormone receptor-positive breast cancer will either jog slowly three times a w…

This trial tests a blended e-health program designed to help women with breast or gynecologic cancer cope with fear of their cancer returning or worsening. The program combines remote group sessions with online modules that teach skills to manage unhelpful thoughts and promote he…

This study compares two ways to treat breast cancer that has spread to nearby lymph nodes: targeted radiotherapy or surgical removal of the nodes. The goal is to see which approach better preserves arm function and reduces the risk of long-term arm swelling. About 1,060 adults wi…

This study tests whether an online nutrition education website, Cook for Your Life, can help breast cancer patients manage side effects like diarrhea and constipation during chemotherapy. About 50 adults with stage I-III breast cancer will use the website alongside standard care.…

This study tests if a steroid mouthwash can prevent or reduce mouth sores caused by the cancer drug datopotamab deruxtecan (Dato-DXd). About 100 adults with advanced breast or lung cancer will use the mouthwash and be monitored for 12 weeks. The goal is to see if this simple step…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests whether psilocybin, the active ingredient in magic mushrooms, can help relieve severe pain in people with advanced cancer when opioids don't work. Fifteen participants will receive psilocybin capsules along with therapy sessions. The goal is to see if this approa…

This trial tests whether adding a nurse-led education and support program to standard care helps women with non-metastatic breast cancer better manage side effects from hormone therapy. Participants will attend an educational session and receive personalized guidance and phone fo…

This trial tests whether a six-month intermittent fasting plan—fasting for about 14 hours each night and eating within a 10-hour daytime window—is something women with early-stage, hormone-positive breast cancer can stick to while on hormone therapy. The goal is to see if this ea…

This study compares two types of nerve blocks given before breast cancer surgery (modified radical mastectomy) to see which one helps patients recover better. Sixty women will receive either a newer block called subtransverse interligamentary plane block or the standard thoracic …

This study tests two digital mindfulness programs—one live over Zoom and one self-paced app—to see if they can reduce depression in younger breast cancer survivors. It includes 402 women diagnosed at or before age 50 who finished cancer treatment at least 6 months ago and have el…

This study tests whether taking tart cherry concentrate and fish oil together for 12 weeks can improve joint function and reduce pain in breast cancer patients who have joint pain from their hormone therapy (aromatase inhibitors). The trial will enroll 30 women who are overweight…

This study tests whether a guided digital self-hypnosis program can reduce hot flashes in women with breast cancer who are on hormone therapy. Hot flashes are a common side effect that often leads patients to stop treatment, raising the risk of cancer returning. Over three weeks,…

This study tests a two-day cognitive behavioral therapy (CBT) program to help breast cancer survivors manage joint and muscle pain caused by their hormone-blocking medication. The goal is to reduce pain, improve quality of life, and help patients stay on their prescribed treatmen…

This trial tests whether Acceptance and Commitment Therapy (ACT), delivered through telehealth group sessions, can help reduce cancer-related distress in patients with incurable hepatobiliary or breast cancer. Participants will learn to cope with difficult thoughts and emotions w…

This trial tests whether olanzapine can replace dexamethasone in preventing delayed nausea and vomiting after chemotherapy in breast cancer patients who have metabolic risk factors like diabetes or obesity. Participants receive either an olanzapine-based regimen or the standard d…

This study tests whether a therapy called Meaning-Centered Psychotherapy for Latinos (MCP-L) can help reduce anxiety and depression in 300 Latino patients with advanced cancer. Participants receive either MCP-L or standard cognitive behavioral therapy over about 3 months. The goa…

This study tests a navigation program for cancer patients starting immunotherapy. The program helps with essential needs like food, transportation, and housing, and tracks side effects. Researchers want to see if this support helps patients continue their treatment and improves t…

This trial tests whether a combination of two ultrasound-guided nerve blocks (PECS II and superficial PIP) can provide pain relief and recovery quality comparable to the standard thoracic paravertebral block after mastectomy. The standard block is effective but carries a risk of …

This trial tests whether Yunzhi essence, a mushroom extract from Coriolus versicolor, can improve quality of life for people with advanced cancer. Participants take either the extract or a placebo for six months, while researchers measure changes in well-being, survival, and immu…

This trial tests whether a virtual reality-based mindfulness program can reduce anxiety, fatigue, and sleep problems while improving comfort in women newly diagnosed with breast cancer who are about to start chemotherapy. Half of the 50 participants will use the VR mindfulness se…

This trial tests whether combining a video game exercise program (Nintendo Ring Fit Adventure) with Acceptance and Commitment Therapy (ACT) can reduce depression and anxiety in breast cancer survivors. About 120 participants will be randomly assigned to the combined program, ACT …

This study tests a minimally invasive technique called endoscopic nipple-sparing mastectomy for women with breast cancer or high genetic risk. Surgeons remove breast tissue through a small side incision using a camera, then reconstruct the breast immediately with an implant. The …

This trial tests whether ear acupressure (stimulating specific points on the ear with bean seeds) combined with a low dose of the steroid dexamethasone can prevent nausea and vomiting caused by the breast cancer drug trastuzumab deruxtecan. About 74 breast cancer patients receivi…

This study tests whether ear acupressure (stimulating specific points on the ear with bean seeds) combined with a low dose of dexamethasone can prevent nausea and vomiting caused by a common chemotherapy regimen (docetaxel plus cyclophosphamide) in breast cancer patients. Partici…

This phase II trial tests whether fisetin, a natural substance found in strawberries, can improve physical function in postmenopausal women who have had chemotherapy for stage I-III breast cancer. Chemotherapy can cause a buildup of aged, non-dividing cells called senescent cells…

This study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…

This study tests whether special hairstyling methods — like braids, cornrows, or a conditioner-and-water mix — can help scalp cooling caps work better to prevent hair loss during chemotherapy. It focuses on people with curly or kinky hair (types 3 and 4), who have been underrepre…

This pilot study tests a remotely delivered physical activity program designed to help breast cancer survivors increase their weekly exercise. Participants are assigned to either an affect-based or effort-based exercise prescription and receive coaching sessions. Those who are no…

This study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …

This study tests a new program called Open Door for Cancer (OD-C) designed to help older adults (65+) who have been diagnosed with breast, colorectal, lung, or prostate cancer and are feeling depressed. The program aims to make it easier for them to start mental health care. Rese…

This phase 2 trial tests whether a combination of olanzapine and ondansetron can prevent nausea and vomiting caused by high-dose cisplatin chemotherapy in people with solid tumors. The approach aims to reduce steroid use by omitting dexamethasone on days 2 through 4. The study en…

This trial tests an app called Access My Breast Cancer Care, designed to help breast cancer patients manage their treatment journey. The app includes educational resources, a calendar, symptom tracker, and a community forum. Researchers will compare app users to those receiving s…

This study compares two types of nerve blocks for pain relief in women undergoing breast cancer surgery. One group receives a single-level block, while another receives a two-level block, with some patients also getting the medication dexmedetomidine. The goal is to see which app…

This study looks at whether a structured 12-week exercise program can improve fitness and recovery in women who have had DIEP flap breast reconstruction after mastectomy. Half of the 78 participants will follow the exercise program, while the other half will receive standard care…

This study tests an 8-week nurse-led self-management program for women with breast cancer who experience taste changes from taxane-based chemotherapy. The program includes education, symptom tracking, and personalized advice to help with eating and nutrition. Researchers will mea…

This study compares two types of nerve blocks given before modified radical mastectomy to see which provides better pain relief and reduces the need for strong painkillers. Eighty women scheduled for surgery will receive one of the two blocks, and researchers will track their pai…

This Phase 3 trial tests whether Nuvastatic 300 mg capsules can reduce the crushing fatigue that often comes with chemotherapy. About 250 women with metastatic triple-negative breast cancer will take either the supplement or a placebo three times daily for 60 days while continuin…

This study tests whether a nicotine cessation program can help women with breast cancer quit nicotine before reconstructive surgery. About 20 women who use nicotine and are scheduled for mastectomy or lumpectomy with reconstruction will take part. The program includes up to four …

This study looks at whether adding hyperbaric oxygen therapy to a structured exercise program can reduce joint and muscle pain caused by aromatase inhibitors in breast cancer survivors. Forty older survivors with pain will either do exercise alone or exercise plus daily hyperbari…

This study tests whether a non-invasive device that gently stimulates a nerve in the ear can help prevent nausea caused by chemotherapy in breast cancer patients. Participants use the device twice daily around their chemo sessions, alongside standard anti-nausea medication. The g…

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This study tests two different nerve block techniques—bilevel erector spinae plane block and pecto-serratus block—to see which provides better pain relief after modified radical mastectomy in breast cancer patients. Sixty women will be enrolled and their painkiller use and pain s…

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This study looks at people who have a gene variant (called a secondary finding) that was found during genetic testing for another reason. Researchers want to understand how these variants affect health, how people respond to the news, and whether they follow medical advice. Up to…

This pilot study tests whether a special type of PET/MRI scan can monitor how triple-negative breast cancer responds to immunotherapy. Twenty patients will get three scans over their first two treatment cycles. The results won't change their care but could help design larger stud…

This study is testing whether a special PET/MRI scan using an investigational tracer called [18F]FMISO can help monitor how well chemotherapy works in people with HER2-positive breast cancer. The study involves 25 patients and is for imaging purposes only—it will not change their…

This study looks at the best times to send messages that encourage physical activity to older cancer survivors (65+) who have chronic pain. About 50 participants will wear an activity tracker and rate their pain four times a day using a smartphone app. The goal is to see if certa…

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This study tests a simple blood test (liquid biopsy) to see if it can tell which triple-negative breast cancer patients will benefit from the drug capecitabine after standard chemotherapy. About 40 adults with leftover cancer after chemo will give blood samples before and during …

This study is creating a decision aid called TA-DA to help people with advanced cancer talk with their doctors about whether to try more treatments after several have already failed. The tool is designed to support shared decision-making. Researchers will test it with 155 patient…

This early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal…

This study is observing about 800 adults with advanced breast cancer (HER2-positive, low, or ultralow) who are receiving the drug trastuzumab deruxtecan as part of their normal care in Germany. Researchers are tracking how long patients stay on the drug before switching treatment…

This observational study is following about 2,400 adults with non-small cell lung cancer or breast cancer to see how biomarkers, including whole-genome sequencing, relate to their outcomes. Participants receive their usual cancer care, and researchers track progression-free survi…

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…

This study is creating a large collection of mammogram images, blood samples, and health information from 10,000 women getting routine screening mammograms. The goal is to build a resource for future research on breast cancer and women's health. Participants provide a blood sampl…

This study is testing a new web and mobile app called SHIELD, designed to support women with hormone receptor-positive breast cancer who are on long-term hormone therapy. The goal is to see if the app is easy to use and helpful for managing treatment. About 30 women will particip…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study will follow about 109 women in Gulf Cooperation Council (GCC) countries who have a certain type of advanced breast cancer (HR-positive, HER2-low or ultra-low) and are taking the drug trastuzumab deruxtecan after hormone therapy stopped working. Researchers want to see …

This trial tests a new imaging method called ultrasound optical tomography (UOT), which combines ultrasound and laser light to create images of tissues inside the body. The goal is to see how deep the technique can image and how well it can measure tissue oxygenation in healthy v…

This study aims to help Black individuals and their families in Houston learn about their risk for hereditary cancers like breast and colorectal cancer. Researchers will use a simple questionnaire and remote genetic counseling to connect people with testing. The goal is to make g…

This study builds a database of 1000 breast cancer survivors aged 50 or younger who have dense breast tissue. Researchers will track their MRI scans over time to see if MRI helps find new cancers that mammograms might miss. No new treatments are tested; the goal is to gather info…

This study is testing whether a special PET/CT scan that looks for a protein called PSMA can help predict resistance to anti-androgen therapy in people with a specific type of metastatic breast cancer (HER2-negative, AR-positive). About 13 participants will receive an injection o…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study aims to understand why some breast cancers become resistant to therapy. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in cancer cells tha…

This study looks at whether an artificial intelligence (AI) tool can safely and accurately help breast cancer patients learn about their condition and treatment. About 35 adults with breast cancer will use the AI tool and answer surveys. The goal is to see if the tool is helpful …

This early-stage study tests a new type of marker that shows up better on ultrasound for people with breast cancer that has spread to lymph nodes. The marker is placed in the lymph node to help doctors find and remove the right node during surgery. The goal is to see if this mark…

This study looks back at medical records of 250 people with a rare type of breast cancer called apocrine lobular carcinoma. Researchers want to understand how this cancer behaves, what treatments patients received, and how they did over time. No new treatments are tested — the go…

The AURORA study is collecting tumor and blood samples from 1,300 people with metastatic breast cancer across Europe. By analyzing genetic changes in both the original and metastatic tumors, researchers hope to understand why some patients respond well to therapy while others do …

This study follows premenopausal women with a common type of early breast cancer to see how well different treatments work over time. Participants either receive hormone therapy (with or without ovarian suppression) or chemotherapy followed by hormone therapy. The goal is to unde…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study looks at how imaging settings and biological factors affect texture features in mammograms. Researchers will use an AI tool to analyze mammograms from 200 women undergoing mastectomy. The goal is to understand these influences to make AI-based breast cancer detection m…

This study is for breast cancer patients receiving certain chemotherapies that can harm the heart. Researchers want to see if a genetic marker called TRPC6 can predict who will develop heart problems. By analyzing blood samples, they hope to find early warning signs and ways to p…

This study aims to make a community weight loss program called TOPS more helpful for breast cancer survivors. Researchers will first gather feedback from survivors in focus groups, then use that feedback to tailor the program. The study will enroll 25 women who have finished prim…

This study is a large registry that will follow about 2,000 adults in China with a type of advanced breast cancer called HR+/HER2- (including HER2-low, HER2-ultralow, and HER2-null). The goal is to describe the patients' characteristics, genetic testing, treatment patterns, and o…

This study is looking at how different treatments given before surgery (like chemo, radiation, or hormone therapy) affect breast cancer patients' response and long-term survival. Researchers will compare results based on the type of treatment and patient characteristics. The goal…

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This study looks at how the location of treatment affects whether people with early-stage HER2-positive breast cancer stick to their therapy plan. Researchers will compare patients who have to travel far for treatment with those who don't. The goal is to see if making treatment m…

This study tests whether an 8-week program using Instagram posts and podcast episodes can improve breast cancer awareness and screening habits in women aged 20 to 39. Participants follow a dedicated Instagram account and listen to podcast content designed to educate about symptom…

This study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…

This observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…

This trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…

This study tests whether adding genetic assessment and verified family history to standard risk models can better classify breast cancer risk in women already considered at moderately increased or high risk. Participants receive genetic counseling and, if eligible, genetic testin…

This study looks at whether testing bone marrow for hidden cancer cells can help predict breast cancer recurrence in women who have completed treatment within the past five years. Researchers will collect blood and bone marrow samples from 600 women at increased risk of relapse. …

This study looks at how the timing of a blood test that detects tumor DNA (ctDNA) affects understanding of prognosis and treatment choices in people with advanced HR+/HER2- breast cancer. Researchers will follow 400 participants to see how ctDNA levels and gene mutations relate t…

This study tests whether a special PET scan that tracks Granzyme B—a molecule released by active immune cells—can predict how well immunotherapy works in people with advanced triple-negative breast cancer. Thirty participants will receive the scan before and after two cycles of i…

This study tests whether measuring calcium buildup in heart arteries from routine radiotherapy planning CT scans can identify breast cancer patients at risk for heart disease. Researchers will share this personalized risk information with patients and their doctors to see if it i…

This study tests whether having a specialist review genetic test results and guide treatment decisions can increase the use of targeted therapies for people with advanced solid tumors, including breast, lung, colorectal, and bladder cancers. Participants will have their tumor or …

This study follows breast cancer patients who are receiving targeted therapy to see if they develop arm swelling, known as lymphedema. Researchers use two devices—a Perometer and a SOZO device—to measure changes in arm volume and fluid levels. The goal is to detect lymphedema ear…

This study looks at the bacteria living in the mouth, stool, and tumors of Colombian adults with advanced cancers of the stomach, colon, breast, cervix, or head and neck who are starting immunotherapy as standard care. Researchers will compare these microbial profiles to those of…

This study uses ultra-high frequency ultrasound (UHFUS) and a green dye to map lymphatic channels in the arms of breast cancer patients scheduled for lymph node surgery. The goal is to better understand normal lymphatic anatomy, which could help reduce the risk of lymphedema (arm…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…

This study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …

This study investigates the challenges and supports available for breast cancer diagnosis in Tanzania. Researchers will interview breast cancer survivors, patient advocates, and healthcare personnel to identify barriers to hormone receptor testing. The goal is to gather informati…

The MILES Study is tracking 100 women recently diagnosed with early-stage breast cancer to see how their diet and physical activity change over time. Participants fill out surveys and provide urine samples, which researchers analyze for chemical markers. The goal is to develop si…

This study watches for heart changes in 150 adults receiving chest radiation for lung, esophageal, breast, or thymus cancer. Researchers will check heart markers, electrical activity, and immune cells at the end of treatment and up to 3 months later. The goal is to find early sig…

This study collects tumor tissue and blood samples from 10,000 women with breast cancer to build a large biorepository. Researchers will analyze these samples to find molecular markers that may predict how well a patient responds to therapy. The goal is to better understand breas…

This study aims to screen 450 early-stage breast cancer survivors for prediabetes, diabetes, high cholesterol, and heart disease risk. Participants complete surveys and provide lab results, and those with risk factors are directed to community resources. The goal is to catch and …

This study looks at whether a program called 'Couples Coping Together Against Cancer' is helpful and practical for people with advanced cancers like stage IV breast cancer, glioblastoma, or lung cancer, and their partners. Researchers at City of Hope will enroll 160 couples to se…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study looks at breast cancer that has spread to the brain. Researchers want to understand how much of the drug trastuzumab deruxtecan gets into the fluid around the brain and spinal cord, and whether that amount relates to how well the drug shrinks brain tumors. About 60 adu…

This study aims to understand how the immune system reacts to a common breast cancer treatment combination of letrozole and abemaciclib. Researchers will collect tumor and blood samples from 60 postmenopausal women with hormone receptor-positive breast cancer before and after two…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study explores whether using ChatGPT to create personalized educational materials helps patients better understand their breast reconstruction options before surgery. Participants scheduled for a breast reconstruction consultation are randomly assigned to receive either Chat…

This study is following over 6,000 breast cancer patients in Germany to see what treatments they actually receive in routine care and how they fare over time. Researchers are collecting data on treatment patterns, survival, and quality of life from patients with early and advance…